Publications
Publications
April, 2026
We're excited to announce that PETAL's latest manuscript, "Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma" has been published in Expert Opinion On Pharmacotherapy.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We're excited to announce that PETAL's latest manuscript, "Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma" has been published in Expert Opinion On Pharmacotherapy.
March, 2026
We're excited to announce that PETAL's latest manuscript, "Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study" has been published in Leukemia and Lymphoma.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
We're excited to announce that PETAL's latest manuscript, "Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium" has been published in Leukemia and Lymphoma.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
December. 2025
We’re excited to announce that our latest manuscript, “Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium,” has been accepted for publication in Blood. This global study, led by PETAL researchers, found that patients with mature nodal T-cell lymphoma whose cancer returns within 12 months face poorer survival outcomes–but may benefit from earlier use of non-chemotherapy treatment approaches.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
June, 2025
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
We are excited to share that our latest
manuscript, "Real-world outcomes
of duvelisib and romidepsin combination
therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL),"
has been accepted for publication in
Blood Advances. Read more on how it
offers critical real-world
evidence supporting a promising
treatment strategy to improve
outcomes and facilitate curative
transplants for patients with
aggressive PTCL.
We are excited to share that our latest manuscript, "Real-world outcomes of
duvelisib and romidepsin combination therapy in relapsed/refractory
peripheral T-cell lymphomas (PTCL)," has been accepted for publication in
Blood Advances. Read more on how it offers critical real-world evidence supporting a promising treatment strategy to improve outcomes and
facilitate curative transplants for patients with aggressive PTCL.
May, 2025
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
We are excited to announce that
our paper, Forecasting optimal treatments
in relapsed/refractory mature T-
and NK-cell lymphomas, has been
published in the British Journal of
Haematology. This collaborative work
leverages machine learning and genomic
insights to predict the most
effective treatment regimens for
aggressive T- and NK-cell lymphomas.
We are excited to announce that our paper, Forecasting optimal treatments
in relapsed/refractory mature T- and NK-cell lymphomas, has been
published in the British Journal of Haematology. This collaborative work
leverages machine learning and genomic insights to predict the most
effective treatment regimens for aggressive T- and NK-cell lymphomas.
October, 2024
Another great milestone achieved for PETAL as our paper, “Global Outcomes and Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas: Results from the PETAL Consortium,” has been accepted for publication in Blood Advances, the open-access journal of the American Society of Hematology.
Another great milestone achieved
for PETAL as our paper,
“Global Outcomes and Prognosis
for Relapsed/Refractory Mature
T-Cell and NK-Cell Lymphomas:
Results from the PETAL
Consortium,”
has been accepted for publication
in Blood Advances, the
open-access journal of the
American Society of Hematology.
Another great milestone achieved for PETAL as our paper, “Global Outcomes and
Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas:
Results from the PETAL Consortium,” has been accepted for publication in Blood
Advances, the open-access journal of the American Society of Hematology.
For Healthcare Professionals
@2026 PETAL Consortium • All rights reserved
For Healthcare Professionals
@2026 PETAL Consortium • All rights reserved